Capricor Therapeutics Inc Net Income per Employee (CAPR), current and historic results, rankings and more, Quarterly Fundamentals - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Sales per Employee
• Income per Employee
• Inventory Turnover
• Asset Turnover
• Receivables Turnover
Capricor Therapeutics inc   (NASDAQ: CAPR)
 

Capricor Therapeutics Inc Net Income per Employee

CAPR's Quarterly Results, Trends, Rankings, Statistics
Capricor Therapeutics Inc recorded a cumulative net loss of $-115 million during 12 month ending in the first quarter 2026.
The Healthcare sector has seen employees of 145 other companies achieving higher income per employee. While Capricor Therapeutics Inc 's total ranking has deteriorated compared to the previous quarter from 3138 to 3472.


What is Income per Employee Ratio?





Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

CAPR Net Income per Employee (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter		 (Jun 30 2025)
II. Quarter		 (Mar 31 2025)
I. Quarter
Y / Y Net Income Change - - - - -
Net Income per Employee (TTM) $ -496,077 -454,736 -354,933 -302,925 -238,375
CAPR's Total Ranking # 3472 # 3138 # 2885 # 3257 # 3738
Seq. Net Income Change - - - - -

CAPR Company Profile >> Back to CAPR Efficiency Comparisons >> Compare CAPR Net Income per Employee to its Competitors

CAPR Net Income per Employee Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 146
Healthcare Sector # 455
Overall Market # 3472

Net Income per Employee Statistics
High Average Low
$ 10,526 $ -107,836 $ -496,077
(Dec 31 2017)   (Mar 31 2026)




  News about Capricor Therapeutics inc Income per employee

Capricor Therapeutics Ramps Up: From Losses to a Lucrative $86.3 Million Public Offering!,

Outline of Facts:1. Public Offering Announcement: - Capricor Therapeutics (NASDAQ: CAPR), a San Diego-based biotechnology company, announced the commencement of a proposed underwritten public offering of its common stock. - The underwriters will have a 30-day option to purchase an additional 15% of shares sold in the offering.2. Recent Financial Performance: - Capricor recorded a cumulative net loss of $28 million during the 12 months ending in Q2 2024. - The companyns ranking in the Major Pharmaceutical Preparations industry shifted from 2358 in Q1 2024 to 3157 by Q2 2024.




Companies with similar Income per Employee for 12 month ending Mar 31 2026, within Healthcare Sector Income per Employee Income 12 month ending Mar 31 2026Number of Employees Mar 31 2026


Date modified: 2026-08-30T14:47:28+00:00




Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.